Antiemesis

David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Lida Nabati, Carli Nesheiwat, Hope S. Rugo, Steven M. Sorscher, Lisa Stucky-Marshal, Barbara Todaro, Susan Urba

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

Original languageEnglish (US)
Pages (from-to)572-595
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Vomiting
Nausea
Guidelines
Granisetron
Transdermal Patch
Drug Therapy
Dexamethasone
Quality of Life
Radiation
Therapeutics
Neoplasms

Keywords

  • 5-HT3-receptor antagonists
  • Antiemesis
  • Chemotherapy-induced
  • NCCN Clinical Practice Guidelines
  • NK-1-receptor antagonists
  • Nausea and vomiting

ASJC Scopus subject areas

  • Oncology

Cite this

Ettinger, D. S., Armstrong, D. K., Barbour, S., Berger, M. J., Bierman, P. J., Bradbury, B., ... Urba, S. (2009). Antiemesis. JNCCN Journal of the National Comprehensive Cancer Network, 7(5), 572-595. https://doi.org/10.6004/jnccn.2009.0039

Antiemesis. / Ettinger, David S.; Armstrong, Debra K.; Barbour, Sally; Berger, Michael J.; Bierman, Philip J.; Bradbury, Bob; Ellis, Georgianna; Kirkegaard, Steve; Kloth, Dwight D.; Kris, Mark G.; Lim, Dean; Markiewicz, Michael Anne; Nabati, Lida; Nesheiwat, Carli; Rugo, Hope S.; Sorscher, Steven M.; Stucky-Marshal, Lisa; Todaro, Barbara; Urba, Susan.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 7, No. 5, 05.2009, p. 572-595.

Research output: Contribution to journalReview article

Ettinger, DS, Armstrong, DK, Barbour, S, Berger, MJ, Bierman, PJ, Bradbury, B, Ellis, G, Kirkegaard, S, Kloth, DD, Kris, MG, Lim, D, Markiewicz, MA, Nabati, L, Nesheiwat, C, Rugo, HS, Sorscher, SM, Stucky-Marshal, L, Todaro, B & Urba, S 2009, 'Antiemesis', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 5, pp. 572-595. https://doi.org/10.6004/jnccn.2009.0039
Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B et al. Antiemesis. JNCCN Journal of the National Comprehensive Cancer Network. 2009 May;7(5):572-595. https://doi.org/10.6004/jnccn.2009.0039
Ettinger, David S. ; Armstrong, Debra K. ; Barbour, Sally ; Berger, Michael J. ; Bierman, Philip J. ; Bradbury, Bob ; Ellis, Georgianna ; Kirkegaard, Steve ; Kloth, Dwight D. ; Kris, Mark G. ; Lim, Dean ; Markiewicz, Michael Anne ; Nabati, Lida ; Nesheiwat, Carli ; Rugo, Hope S. ; Sorscher, Steven M. ; Stucky-Marshal, Lisa ; Todaro, Barbara ; Urba, Susan. / Antiemesis. In: JNCCN Journal of the National Comprehensive Cancer Network. 2009 ; Vol. 7, No. 5. pp. 572-595.
@article{c8e92e23cee940e98f134590d94b37d7,
title = "Antiemesis",
abstract = "Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.",
keywords = "5-HT3-receptor antagonists, Antiemesis, Chemotherapy-induced, NCCN Clinical Practice Guidelines, NK-1-receptor antagonists, Nausea and vomiting",
author = "Ettinger, {David S.} and Armstrong, {Debra K.} and Sally Barbour and Berger, {Michael J.} and Bierman, {Philip J.} and Bob Bradbury and Georgianna Ellis and Steve Kirkegaard and Kloth, {Dwight D.} and Kris, {Mark G.} and Dean Lim and Markiewicz, {Michael Anne} and Lida Nabati and Carli Nesheiwat and Rugo, {Hope S.} and Sorscher, {Steven M.} and Lisa Stucky-Marshal and Barbara Todaro and Susan Urba",
year = "2009",
month = "5",
doi = "10.6004/jnccn.2009.0039",
language = "English (US)",
volume = "7",
pages = "572--595",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Antiemesis

AU - Ettinger, David S.

AU - Armstrong, Debra K.

AU - Barbour, Sally

AU - Berger, Michael J.

AU - Bierman, Philip J.

AU - Bradbury, Bob

AU - Ellis, Georgianna

AU - Kirkegaard, Steve

AU - Kloth, Dwight D.

AU - Kris, Mark G.

AU - Lim, Dean

AU - Markiewicz, Michael Anne

AU - Nabati, Lida

AU - Nesheiwat, Carli

AU - Rugo, Hope S.

AU - Sorscher, Steven M.

AU - Stucky-Marshal, Lisa

AU - Todaro, Barbara

AU - Urba, Susan

PY - 2009/5

Y1 - 2009/5

N2 - Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

AB - Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval.

KW - 5-HT3-receptor antagonists

KW - Antiemesis

KW - Chemotherapy-induced

KW - NCCN Clinical Practice Guidelines

KW - NK-1-receptor antagonists

KW - Nausea and vomiting

UR - http://www.scopus.com/inward/record.url?scp=66749129673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66749129673&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2009.0039

DO - 10.6004/jnccn.2009.0039

M3 - Review article

C2 - 19460282

AN - SCOPUS:66749129673

VL - 7

SP - 572

EP - 595

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -